An observational study in Hodgkin Lymphoma, sponsored by Superior University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Superior University · Observational
Pulmonary toxicity during Hodgkin lymphoma treatment is significant for a variety of reasons, ranging from clinical care to therapeutic innovation and patient outcomes.
Understanding chemotherapy-induced pulmonary issues, particularly bleomycin-induced toxicity, might enhance treatment efficacy, side effects, and quality of life for Hodgkin lymphoma patients. For Hodgkin lymphoma chemotherapy patients with pulmonary difficulties, which result in significant patient morbidity and mortality, early detection, proactive surveillance, and rapid management are required. Identifying the prevalence, risk factors, and clinical signs of pulmonary toxicity helps clinicians stratify treatment.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 214 is above the median of 136 across 625 observational studies indexed under Lymphoma.
Browse Lymphoma studies →Superior University is the lead sponsor of 242 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
to check the Frequency of Pulmonary Toxicity in Patients Treated for Hodgkin Lymphoma
Exclusion Criteria:
To determine treatment-induced pulmonary toxicity prevalence and risk factors in Hodgkin lymphoma patients during chemotherapy or radiation therapy.
high-resolution computed tomography
An HRCT (high-resolution computed tomography) scan is a type of CT scan healthcare providers use to get detailed images of your lungs. Providers most commonly use it to diagnose and monitor interstitial lung diseases and conditions that affect your small airways and alveoli (air sacs).
Time frame: 12 Months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Superior University